169 related articles for article (PubMed ID: 24090875)
1. Effects of ageing, prolonged estrogen deficiency and zoledronate on bone tissue mineral distribution.
Brennan MA; Gleeson JP; O'Brien FJ; McNamara LM
J Mech Behav Biomed Mater; 2014 Jan; 29():161-70. PubMed ID: 24090875
[TBL] [Abstract][Full Text] [Related]
2. The effects of estrogen deficiency and bisphosphonate treatment on tissue mineralisation and stiffness in an ovine model of osteoporosis.
Brennan O; Kennedy OD; Lee TC; Rackard SM; O'Brien FJ; McNamara LM
J Biomech; 2011 Feb; 44(3):386-90. PubMed ID: 21093863
[TBL] [Abstract][Full Text] [Related]
3. Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis.
Brennan O; Kennedy OD; Lee TC; Rackard SM; O'Brien FJ
J Orthop Res; 2011 Mar; 29(3):419-24. PubMed ID: 20886644
[TBL] [Abstract][Full Text] [Related]
4. Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study.
Dempster DW; Roschger P; Misof BM; Zhou H; Paschalis EP; Alam J; Ruff VA; Klaushofer K; Taylor KA
J Bone Miner Res; 2016 Aug; 31(8):1527-35. PubMed ID: 26931279
[TBL] [Abstract][Full Text] [Related]
5. Site specific increase in heterogeneity of trabecular bone tissue mineral during oestrogen deficiency.
Brennan MA; Gleeson JP; Browne M; O'Brien FJ; Thurner PJ; McNamara LM
Eur Cell Mater; 2011 May; 21():396-406. PubMed ID: 21574136
[TBL] [Abstract][Full Text] [Related]
6. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
[TBL] [Abstract][Full Text] [Related]
7. Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort.
Misof BM; Roschger P; Gabriel D; Paschalis EP; Eriksen EF; Recker RR; Gasser JA; Klaushofer K
J Bone Miner Res; 2013 Mar; 28(3):442-8. PubMed ID: 23044788
[TBL] [Abstract][Full Text] [Related]
8. Effects of Odanacatib on bone mineralization density distribution in thoracic spine and femora of ovariectomized adult rhesus monkeys: a quantitative backscattered electron imaging study.
Fratzl-Zelman N; Roschger P; Fisher JE; Duong LT; Klaushofer K
Calcif Tissue Int; 2013 Mar; 92(3):261-9. PubMed ID: 23179105
[TBL] [Abstract][Full Text] [Related]
9. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Misof BM; Paschalis EP; Blouin S; Fratzl-Zelman N; Klaushofer K; Roschger P
J Bone Miner Res; 2010 Nov; 25(11):2297-303. PubMed ID: 20683883
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis.
Little DG; Smith NC; Williams PR; Briody JN; Bilston LE; Smith EJ; Gardiner EM; Cowell CT
J Bone Miner Res; 2003 Jul; 18(7):1300-7. PubMed ID: 12854841
[TBL] [Abstract][Full Text] [Related]
11. The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength.
Yao W; Cheng Z; Koester KJ; Ager JW; Balooch M; Pham A; Chefo S; Busse C; Ritchie RO; Lane NE
Bone; 2007 Nov; 41(5):804-12. PubMed ID: 17825637
[TBL] [Abstract][Full Text] [Related]
12. Influence of early zoledronic acid administration on bone marrow fat in ovariectomized rats.
Li GW; Xu Z; Chang SX; Zhou L; Wang XY; Nian H; Shi X
Endocrinology; 2014 Dec; 155(12):4731-8. PubMed ID: 25243855
[TBL] [Abstract][Full Text] [Related]
13. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.
Zoehrer R; Roschger P; Paschalis EP; Hofstaetter JG; Durchschlag E; Fratzl P; Phipps R; Klaushofer K
J Bone Miner Res; 2006 Jul; 21(7):1106-12. PubMed ID: 16813531
[TBL] [Abstract][Full Text] [Related]
14. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.
McDonald MM; Dulai S; Godfrey C; Amanat N; Sztynda T; Little DG
Bone; 2008 Oct; 43(4):653-62. PubMed ID: 18582604
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
Uyar Y; Baytur Y; Inceboz U; Demir BC; Gumuser G; Ozbilgin K
Maturitas; 2009 Jul; 63(3):261-7. PubMed ID: 19386450
[TBL] [Abstract][Full Text] [Related]
16. Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys.
Yamagami Y; Mashiba T; Iwata K; Tanaka M; Nozaki K; Yamamoto T
Bone; 2013 May; 54(1):1-7. PubMed ID: 23356990
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates do not alter the rate of secondary mineralization.
Fuchs RK; Faillace ME; Allen MR; Phipps RJ; Miller LM; Burr DB
Bone; 2011 Oct; 49(4):701-5. PubMed ID: 21619951
[TBL] [Abstract][Full Text] [Related]
18. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).
Roschger P; Lombardi A; Misof BM; Maier G; Fratzl-Zelman N; Fratzl P; Klaushofer K
J Bone Miner Res; 2010 Jan; 25(1):48-55. PubMed ID: 19580465
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis.
Simm PJ; Johannesen J; Briody J; McQuade M; Hsu B; Bridge C; Little DG; Cowell CT; Munns CF
Bone; 2011 Nov; 49(5):939-43. PubMed ID: 21820091
[TBL] [Abstract][Full Text] [Related]
20. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid.
Gamsjaeger S; Buchinger B; Zwettler E; Recker R; Black D; Gasser JA; Eriksen EF; Klaushofer K; Paschalis EP
J Bone Miner Res; 2011 Jan; 26(1):12-8. PubMed ID: 20645415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
